Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Asset Writedowns and Impairment (2024 - 2025)

Fennec Pharmaceuticals (FENC) has disclosed Asset Writedowns and Impairment for 4 consecutive years, with -$1.7 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Asset Writedowns and Impairment changed N/A year-over-year to -$1.7 million, compared with a TTM value of -$517000.0 through Sep 2025, changed N/A, and an annual FY2024 reading of $517000.0, changed N/A over the prior year.
  • Asset Writedowns and Impairment was -$1.7 million for Q3 2025 at Fennec Pharmaceuticals, down from $1.1 million in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $1.1 million in Q2 2025 and bottomed at -$1.7 million in Q3 2025.